No Matter The Market, Options Trading Could Earn You More

There’s no way to predict Wall Street’s future, but by using options trading, you have the opportunity to take advantage of any trend. Expert Wendy Kirkland explains how in her latest free guide.

Paul Sekhri Biography and Net Worth

Director of Veeva Systems

Paul Sekhri has more than 25 years’ experience in life sciences, having served in executive leadership positions at some of the most widely regarded pharmaceutical companies in the world. He is President and CEO of eGenesis, a biotechnology company focused on xenotransplantation. Previously, Paul served as president and CEO of Lycera, an innovative biopharmaceutical company focused on treatments for autoimmune diseases and cancer. Prior to Lycera, he was operating partner at Highline Therapeutics, a biotech incubator launched by Versant Ventures. Paul also served as senior vice president, integrated care at Sanofi where he led the creation of innovative solutions and business models to meet patient needs. Before Sanofi, Paul led global business development and was chief strategy officer at Teva. He also served as operating partner and head, biotech ops
group at TPG Biotech, the life sciences venture arm of the global private investment firm TPG, where he was responsible for a portfolio of more than 50 life sciences companies. He has held the roles of founder, president, and chief executive officer of Cerimon Pharmaceuticals; president and chief business officer of ARIAD Pharmaceuticals; and partner for healthcare investments of New Leaf Ventures. Paul spent four years at Novartis, where he held various senior positions, including senior vice president, head of global search and evaluation, business development and licensing, and global head, early commercial development, where he developed the disease area strategy, and founded the early commercial development department.

Paul has served as a director on more than 24 private and public company boards, including BiomX, Ipsen, Compugen, Alpine Immune Sciences, Pharming N.V., Topas Therapeutics, Petra Pharma Corporation, Enumeral Biomedical Holdings, Inc., KAI Pharmaceuticals, Intercept Pharmaceuticals, Macrogenics, PatientSafe Solutions, Tandem Diabetes, and as board advisor to IMS Health.

Paul completed post-graduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine and received his bachelor of
science degree in zoology from the University of Maryland, College Park.

What is Paul J. Sekhri's net worth?: The estimated net worth of Paul J. Sekhri is at least $3.08 million as of March 3rd, 2023. Mr. Sekhri owns 16,381 shares of Veeva Systems stock worth more than $3,084,706 as of June 7th. This net worth evaluation does not reflect any other investments that Mr. Sekhri may own. Learn More about Paul J. Sekhri's net worth.
How do I contact Paul J. Sekhri?: The corporate mailing address for Mr. Sekhri and other Veeva Systems executives is 4280 HACIENDA DRIVE, PLEASANTON CA, 94588. Veeva Systems can also be reached via phone at (925) 452-6500 and via email at [email protected]. Learn More on Paul J. Sekhri's contact information.
Has Paul J. Sekhri been buying or selling shares of Veeva Systems?: Paul J. Sekhri has not been actively trading shares of Veeva Systems during the last ninety days. Most recently, Paul J. Sekhri sold 2,658 shares of the business's stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $181.93, for a transaction totalling $483,569.94. Following the completion of the sale, the director now directly owns 16,381 shares of the company's stock, valued at $2,980,195.33. Learn More on Paul J. Sekhri's trading history.
Who are Veeva Systems' active insiders?: Veeva Systems' insider roster includes Timothy Barabe (Director), Brent Bowman (CFO), Timothy Cabral (CFO), Paul Chamberlain (Director), Ronald Codd (Director), Jonathan Faddis (SVP), Mary Hedley (Director), Frederic Lequient (SVP), Alan Mateo (EVP), Michele O'connor (CAO), Thomas Schwenger (COO), Paul Sekhri (Director), Matthew Wallach (President), and Eleni Zuppas (CMO). Learn More on Veeva Systems' active insiders.
Are insiders buying or selling shares of Veeva Systems?: In the last year, insiders at the technology company sold shares 26 times. They sold a total of 3,134,131 shares worth more than $510,774,506.25. The most recent insider tranaction occured on June, 2nd when Director Timothy S Cabral sold 12,036 shares worth more than $2,407,801.80. Insiders at Veeva Systems own 11.0% of the company. Learn More about insider trades at Veeva Systems.
Information on this page was last updated on 6/2/2023.

Paul J. Sekhri Insider Trading History at Veeva Systems

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/3/2023	Sell	2,658	$181.93	$483,569.94	16,381
3/31/2022	Sell	11,000	$214.02	$2,354,220.00
3/27/2020	Sell	1,854	$145.50	$269,757.00	10,295
12/6/2019	Sell	4,615	$146.11	$674,297.65	11,550
10/4/2019	Sell	628	$151.00	$94,828.00	16,165
6/24/2019	Sell	601	$169.38	$101,797.38	16,494
3/22/2019	Sell	600	$127.53	$76,518.00	16,468
12/26/2018	Sell	601	$85.00	$51,085.00	16,440
12/18/2018	Sell	9,029	$86.68	$782,633.72	18,266
12/3/2018	Sell	6,016	$98.09	$590,109.44	31,459
9/24/2018	Sell	601	$103.67	$62,305.67	11,459
6/25/2018	Sell	1,107	$82.80	$91,659.60	11,432
3/23/2018	Sell	1,108	$75.46	$83,609.68	13,046
2/28/2018	Sell	4,622	$65.00	$300,430.00
12/7/2017	Sell	10,971	$53.83	$590,568.93	27,438
10/11/2016	Sell	17,593	$37.73	$663,783.89	21,108

Paul J. Sekhri Buying and Selling Activity at Veeva Systems

Veeva Systems Company Overview

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Today's Range

Now: $188.87

$187.96

$196.71

50 Day Range

MA: $177.14

$162.60

$198.13

2 Week Range

Now: $188.87

$151.02

$232.26

Volume

1,269,590 shs

Average Volume

1,027,568 shs

Market Capitalization

$30.18 billion

P/E Ratio

59.02

Dividend Yield

N/A

Beta

0.92

Passive Income Powerhouse Unveiled: The Ultimate Play!

From The Oxford Club | Ad

The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas.

Find Out What It Is Right Here.

>>>